Abstract
Amyloid diseases are frequently associated with the appearance of an aberrant form of a protein, whose detection enables early diagnosis. In the case of transthyretin amyloidosis, the aberrant protein – the monomers – constitute the smallest species of the amyloid cascade, which creates engineering opportunities for sensing that remain virtually unexplored. Here, a two-step assay is devised, combining molecular sieving and immunodetection, for quantification of circulating monomeric transthyretin in the plasma. It is shown that mesoporous crystals built from biomolecules can selectively uptake transthyretin monomers up to measurable quantities. Furthermore, it was found that the use of endogenous molecules to produce the host framework drastically reduces unspecific adsorption of plasma proteins at the crystal surface, a feature that was observed with metal-organic frameworks. The assay was used to analyse plasma microsamples of patients and healthy controls. It shows a significant increase in the levels of monomeric transthyretin in the patients, proving its usefulness to establish the monomers as soluble and non-invasive marker of the disease. In addition, the assay can evaluate transthyretin stabilizers, an emergent strategy that broadened the treatment approach to the disease. Sensing the initial event of the transthyretin amyloid cascade with the proposed assay can make the difference for early diagnosis and eliminate the currently adopted invasive biopsies modalities for detection of the final products of the aggregation pathway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National funds through FCT Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior in the framework of the projects Institute for Research and Innovation in Health Sciences (POCI-01-0145-FEDER-007274) and by European Union's Horizon 2020 research and innovation programme under grant agreement No. 952334 (PhasAGE). FCT is gratefully acknowledged for the PhD grant SFRH/BD/151016/2021 (to D.C.). Protein production and purification performed at the i3S Biochemical and Biophysical Technologies Platform. The mass spectrometry analysis done at the Proteomics i3S Scientific Platform with the assistance of Hugo Osorio and the support of the Portuguese Mass Spectrometry Network (ROTEIRO/0028/2013; LISBOA-01-0145-FEDER-022125).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
human blood samples from individuals who requested to perform blood collection with predictive character at the Center for Predictive and Preventive Genetics (CGPP) of the IBMC to evaluate the condition of the pre-symptomatic V30M mutation was submitted by the group Molecular Neurobiology (i3S-Instituto de Investigacao e Inovacao em Saude) and approved by the Ethical Committee of the University of Porto (Report n 36/CEUP/2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
